Skip to main content

J-147

Source index · review incomplete

An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.

Source summary generated July 17, 2026; this date does not indicate completed review.

Cognitive Enhancement97 cited mentions
Track your own protocol free →

Quotes from three independent practitioners, with their sources. Research context only.

What it is and how it works

From the published literature on J-147; the papers are listed at the end. Research summary, not a recommendation.

What it is

J-147 is a small synthetic molecule, not a peptide, developed at the Salk Institute in California from a chemical relative of curcumin (the yellow compound in turmeric). It was found by screening compounds for protection of nerve cells under conditions that mimic ageing and Alzheimer's disease, and it was designed to be taken by mouth. It is an experimental drug candidate and is not approved for any use.

How it works

In mouse studies J-147 raised levels of nerve growth factor and brain-derived neurotrophic factor, two proteins that support the survival and connections of nerve cells. A later study identified ATP synthase, the mitochondrial enzyme that makes the cell's main energy molecule, as a direct target, and reported that partly adjusting its activity shifted energy metabolism in a way linked to protection of ageing cells. Follow-up work reported that J-147 raised levels of acetyl-CoA, a central metabolic building block, and changed fatty-acid handling by the liver. These mechanisms come from mouse and cell experiments only.

What it has been studied for

  • Memory loss in aged Alzheimer's-model mice (animal study)
  • Mitochondrial energy metabolism and ageing in mice (animal and cell studies)
  • Brain ageing and metabolism in rapidly ageing mice (animal study)
  • Diabetic nerve pain and damage (rodent study)

Strength of the evidence

Animal and lab studiesThe published work is mouse, rat and cell research; no completed human trial of J-147 was found as of 2026-11-06.

What the literature reports on safety

The authors of the main mouse study described it as safe in animals, but no human adverse-effect data have been published. J-147 is not approved by the FDA or any regulator and is sold only as a research chemical. A later mouse study reported that it lowered blood fatty-acid levels through liver signalling, an effect whose human relevance is unknown.

Key papers

  1. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice (opens in a new tab)

    Animal study · Prior M, Dargusch R, et al. · Alzheimer's Research and Therapy (2013) · PMID 23673233

    In aged Alzheimer's-model mice, J-147 rescued memory deficits and raised nerve growth factor and brain-derived neurotrophic factor.

  2. The mitochondrial ATP synthase is a shared drug target for aging and dementia (opens in a new tab)

    Lab (in vitro) · Goldberg J, Currais A, et al. · Aging Cell (2018) · PMID 29316249

    Identified mitochondrial ATP synthase as a direct binding target of J-147 and linked it to the compound's protective effects.

  3. Elevating acetyl-CoA levels reduces aspects of brain aging (opens in a new tab)

    Animal study · Currais A, Huang L, et al. · eLife (2019) · PMID 31742554

    In rapidly ageing mice, J-147 raised acetyl-CoA and reduced several markers of brain ageing.

  4. ATP synthase and Alzheimer's disease: putting a spin on the mitochondrial hypothesis (opens in a new tab)

    Review · Ebanks B, Ingram TL, et al. · Aging (Albany NY) (2020) · PMID 32853175

    Reviewed the evidence that ATP synthase is altered in Alzheimer's disease, including its role as the proposed target of J-147.

  5. The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver (opens in a new tab)

    Animal study · Kepchia D, Huang L, et al. · Biomedicine and Pharmacotherapy (2022) · PMID 35051863

    In mice, J-147 lowered blood fatty-acid levels by acting on an energy-sensing signalling pathway in the liver.

  6. A novel curcumin derivative for the treatment of diabetic neuropathy (opens in a new tab)

    Animal study · Daugherty DJ, Marquez A, et al. · Neuropharmacology (2018) · PMID 29122628

    In a rodent model of diabetes, J-147 reduced signs of nerve damage and pain-related behaviour.

Sources checked: PubMed/PMC (E-utilities esummary on every PMID; abstract of the main mouse study read), written 2026-11-06.

Hunter Williams

→ profile

Protocol systematizer

Sources: compound titles first, then mentions

Ask the J-147 Librarian

Answers are generated from captured sources and may omit context or contain errors. Check the supporting passages.

What have the teachers said about J-147? Ask what it is, what they say it does, or where they discuss it. Questions about doses or personal use: ask your own clinician.

AI chat. To generate a reply, your question and recent chat history may be processed by Cloudflare Workers AI, Groq, Google Gemini or OpenRouter, depending on availability. Keep personal health details out of the chat and check the cited sources. Research use only; not medical advice.

Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.

Disclaimer: for research purposes only

All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.

J-147 — Hunter, Taylor, Bachmeyer | Reset Biology